Interestingly, GLP‐1 receptor agonists commercially used for the treatment of T2DM, such as lixisenatide and liraglutide, have been tested on AD mouse models and shown to have neuroprotective effects. This evidence concerns the gene GLP1R and Alzheimer disease.